Skip to main content
SpringerLink
Log in

Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU)

  • Pharmacology Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

A novel nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl) ethyl]-1-nitrosourea (TCNU) tauromustine, has been investigated in a broad anti-tumour screen and, in depth toxicology and initial pharmacokinetics carried out.

TCNU and its two metabolites were found to exhibit equal or better oral efficacy than that of BCNU, CCNU, MeCCNU or chorozotocin against L1210 leukemia, Walker mammary carcinoma, Lewis Lung, Harding Passey melanoma and colon carcinoma C26. The toxicological profile of TCNU after acute and 3 months treatment was similar in mice and rats to that of CCNU, with the exception that, TCNU did not cause the chronic liver disturbances found for CCNU. In dogs treated for 6 weeks with TCNU leucopenia and thrombocytopenia were the major side effects. Parent TCNU was found in all dogs. The absorption was fast, the maximum level being reach after 25 mins and the mean absorption time was 22 mins. The mean half life was 16.1 mins after intravenous and 17.4 after oral administration. The combination of these factors make TCNU an interesting clinical candidate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Johnston TP, McCaleb GS, Montgomery JA: The synthesis of antineoplastic agents XXXII N-nitrosoureas I. J Med Chem 6:669–681, 1963

    Google Scholar 

  2. De Vita V, Carbone P, Owens A, Gold L, Krant M, Edmonson J: Clinical Trials with 1,3-Bis(2-choroethyl)-1-nitro-sourea NSC-409962. Cancer Res 25:1876–1881, 1965

    Google Scholar 

  3. Hansen HH, Selawry PS, Maggia FM, Walker MD: Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res 31:223–227, 1971

    Google Scholar 

  4. Anderson T, McMenamin M, Schein PS: Chlorozotocin, 2-[3-(-2-chloroethyl)-3-nitrosoureido]-D-glucopyranose an antitumor agent with modified bone marrow toxicity. Cancer Res 35:761–765, 1975

    Google Scholar 

  5. Fox PA, Panasci LC, Schein PS: Biological and biochemical properties of 1-(-2-chloroethyl)-3-(B-D-glucopyranosyl)-1-nitrosourea (NSCD 254157), a nitrosourea with reduced bone marrow toxicity. Cancer Res 37:783–787, 1977

    Google Scholar 

  6. Aoshima M, Sakurai Y: Comparative studies on the antitumor activity and the bone marrow toxicity of 1-(B-D-glucopyranosyl)-3-(-2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose. GANN 68:247–250, 1977

    Google Scholar 

  7. Zeller WJ, Eisenbrand G, Fiebig HH; Chemotherapeutic activity of new 2-chloroethylnitrosourea in rat L5222 leukemia: comparison of bifunctional and water-soluble derivatives with 1,3-bis(2-chloroethyl)-1-nitrosourea. J Natl Cancer Inst 60:345–348, 1978

    Google Scholar 

  8. Zeller WJ, Eisenbrand G: Examination of newly synthesized 2-chloroethyl-nitrosoureas on rat leukemia L5222. Oncology 38:39–42, 1981

    Google Scholar 

  9. Panasci LC, Green D, Nagourney R, Fox P, Schein PS: A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice. Cancer Res 37:2615–2618, 1977

    Google Scholar 

  10. Hansch C, Leo A, Schmidt C, Jow PYC: Antitumor structure-activity relationships: Nitrosoureas vs L1210 leukemia. J Med Chem 23:1095–1101, 1980

    Google Scholar 

  11. Oseika R, Glatte P, Pannenbäcker R, Schmidt CG: Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system. Cancer Chemother Pharmacol 11:147–152, 1983

    Google Scholar 

  12. Fredholm B, Gunnarsson K, Jensen G, Müntzing J: Mammary tumour inhibiti on and subacute toxicity in rats of prednimustine and its molecular components chlorambucil and prednisolone. Acta Pharmacol et Toxicol 42:159–163, 1978

    Google Scholar 

  13. Müntzing J, Jensen G, Högberg B: Pilot study on the growth inhibition by estramustine phosphate (Estracyt®) of rat mammary tumours sensitive and insensitive to estrogens. Acta Pharmacol et Toxicol 44:1–6, 1979

    Google Scholar 

  14. Hartley-Asp B, Wilkinson R, Venitt S, Harrap KR: Studies on the mechanism of action of LS 1727, a nitroscarbamate of 19-nortestostrone. Acta Pharmacol et Toxicol 48:129–138, 1981

    Google Scholar 

  15. Berger MR, Aoride J, Schreiber J, Schmähl D, Eisenbrand G: Evaluation of new estrogen-linked 2-chloroethyl-nitrosoureas. Short term anticancer efficacy in methylnitrosoureas-induced rat mammary carcinoma and hormonal activity in mice. J Cancer Clin Oncol 108:148–153, 1984

    Google Scholar 

  16. Wei LS, Katzenellenbogen BS, Robertson DW, Simpson DH, Katzenellenbogen JA: Nitrosourea and nitrosocabamate derivatives of the antiestrogen tamoxifen as potential estrogen receptor-mediated cytotoxic agents in human breast cancer cells. Breast Cancer Res Treat 7:77–90, 1986

    Google Scholar 

  17. Huxtable RJ, Sebring LA: Towards a unifying theory for the actions of taurine. TIPS Dec 1986:481–485, 1986

    Google Scholar 

  18. Ahtee L, Boulin DJ, Paasonen MK: Transport of taurine by normal human blood platelets. Br J Pharmacol 52:245, 1974

    Google Scholar 

  19. Huxtable R, Chubb J: Adrenergic stimulation of taurine transport by the heart. Science 198:409–411, 1977

    Google Scholar 

  20. Vaaden MJ, Oradeu ACI, Marshall J, Lake M: Taurine in the retina: In: Schaffer SW, Baskin SI, Kocsis JJ (eds) The Effects of Taurine on Excitable Tissues. Spectrum Publications Inc USA, 1981, pp 145–160

    Google Scholar 

  21. Christensen HN, Hess B, Riggs TR: Concentration of taurine B-alanine and Triiodothyronine by ascites carcinoma cells. Cancer Res 14:124–127, 1954

    Google Scholar 

  22. Piez KA, Eagle H: The free amino acid pool of cultured human cells. J Biol Chem 231:533–545, 1958

    Google Scholar 

  23. Ishidate M, Sakurai Y, Yoshida T, Satoh H, Imamura H: Experimental studies on chemotherapy of malignant growth employing Yoshida sarcoma animals. VI. Effect of N-bis-B-chloroethyl-aminoacids and their derivatives. GANN, 45:528–531, 1954

    Google Scholar 

  24. Pierson HF, Fisher JM, Rabinovitz M: Modulation by taurine of the toxicity of taumustine, a compound with antitumour activity. J Natl Cancer Inst 75:905–909, 1985

    Google Scholar 

  25. Tauromustine. Drugs of the Future 11:585–587, 1986

    Google Scholar 

  26. Polacek J, Gunnarsson PO, Brandin S: Determination of TCNU, a novel antitumour agent, in plasma by high-performance liquid chromatography. J Chromatog In press

  27. Roed H, Vindeløv LL, Spang-Thomsen M, Christensen IJ, Hansen HH: In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines. Cancer Chemother Pharmacol 19: 315–318, 1987

    Google Scholar 

  28. Day RS, Ziolkowski CHJ, Scudiero DA, Meyer SA, Lubiniecki AS, Girardi AJ, Galloway SM, Bynum GD: Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 288:724–727, 1980

    Google Scholar 

  29. Erickson LC, Laurent G, Sharkey NA, Kohn KW: DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 288:727–729, 1980

    Google Scholar 

  30. Tew KD, Dean SW, Gibson NW: The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethyl-aminosulfonyl) ethyl]-1-nitrosourea (TCNU) on cytotoxicity, DNA cross linking and glutathione reductase in lung carcinoma cell lines. Cancer Chemother Pharmacol 19:291–295(1987)

    Google Scholar 

  31. Molineux G, Schofiled R, Testa NG: The haemopoietic effects of TCNU in mice. Cancer Treat Rep 71:837–842 (1987)

    Google Scholar 

  32. Gunnarsson PO, Vibe-Petersen J, Macpherson IS, Warrington PS, Polacek J, Ellman M, Hansen HH, Smyth JF: Pharmacokinetics of TCNU in cancer patients. Phase I studies. Cancer Chemoth Pharmacol In press

  33. Smyth JF, Macpherson JS, Warrington PS, Kerr ME, Whelan JM, Combleat MA, Leonard RCF: Phase I study of TCNU a novel nitrosourea. Eur J Cancer Clin Oncol 23:1845–1849, 1987

    Google Scholar 

  34. Vibe-Petersen J, Bork E, Møller H, Hansen HH: A phase I clinical evaluation of 1-(2-chloroethyl)-3-/2-(dimethyl-ami-nosulfonyl) ethyl/-1-nitrosourea (TCNU). Eur J Cancer Clin Oncol 23:1837–1843, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. AB Leo, Box 941, S-251 09, Helsingborg, Sweden

    Beryl Hartley-Asp, P. -I. Christensson, K. Gunnarsson, P. O. Gunnarsson, Gunborg Jensen, J. Polacek & A. Stamvik

Authors
  1. Beryl Hartley-Asp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. -I. Christensson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Gunnarsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. O. Gunnarsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gunborg Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Polacek
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Stamvik
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hartley-Asp, B., Christensson, P.I., Gunnarsson, K. et al. Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU). Invest New Drugs 6, 19–30 (1988). https://doi.org/10.1007/BF00170775

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00170775

Key words

Search

Navigation